Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

Summary

The aim of our study is to confirm the relevance of PET using \[68Ga\]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. The prognostic value of positive CXCR4 expression will also be assessed and \[68Ga\]Ga -PentixaFor/FDG discordances explored.

Timeline

Start

2021-09-21

Primary completion

2029-12-21

Completion

2030-05-21

Publications

• Francois C, Carlier T, Touzeau C, Janz A, Dubegny C, Jamet B, Kraeber-Bodere F, Bailly C, Bodet-Milin C. Optimal acquisition time of [68Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol. EJNMMI Res. 2026 Mar 13;16(1):67. doi: 10.1186/s13550-026-01410-2.

Drugs

Indications